During the corresponding time, Invivyd Inc recorded a revenue increase by 21.2 % year on year, sequentially revenue grew by 3.94 %. While revenue at the Invivyd Inc 's corporate clients
Invivyd Inc's Comment on Sales, Marketing and Customers
The company sells its product primarily through third-party specialty distributors and, to a lesser extent, directly to a limited number of infusion centers, healthcare providers, and provider institutions. Shipments are made to sites of care such as provider institutions, infusion centers, and clinics that bill health insurance plans. The company has a third-party logistics agreement with a 3PL Agent responsible for storage, distribution, returns, customer service, logistics, and system support. For the year ended December 31, 2025, net product revenue was derived from sales to third-party specialty distributors and direct sales to select infusion centers, healthcare providers, and provider institutions in the U.S. Three specialty distributors accounted for 46%, 23%, and 17% of total gross sales, respectively. Additionally, the company maintains a relationship with Adimab, which provides antibody discovery, engineering, and optimization services, including agreements for antibody discovery and platform technology use.
In a significant announcement on September 3, 2024, Invivyd, Inc. (Nasdaq: IVVD), has reaffirmed its commitment to tackling COVID-19 with promising data showcasing the effectiveness of its neutralizing monoclonal antibody, PEMGARDA (pemivibart). New in vitro studies revealed that PEMGARDA and the emerging candidate VYD2311 maintain robust neutralizing activity against some of the most prevalent SARS-CoV-2 variants currently circulating, including the formidable KP.3.1.1 and LB.1 strains.As the Centers for Disease Control and Prevention (CDC) reported, the KP.3.1.1 variant accounted for an alarming 42.2% of SARS-CoV-2 infections in the two weeks leading up to the announcement. This variant represents the only...
Invivyd Announces Partnership with FDA for Expedited EUA Pathway for COVID-19 TreatmentInvivyd, a leading biopharmaceutical company focused on combating viral infections, has recently announced its collaboration with the U.S. Food and Drug Administration (FDA) to establish a streamlined emergency use authorization (EUA) pathway for potential treatments targeting symptomatic COVID-19. This significant development highlights Invivyd s commitment to finding rapid and effective solutions to combat the ongoing pandemic.Under this partnership, Invivyd aims to leverage its proprietary monoclonal antibody (mAb) technology platform and advanced engineering capabilities to develop innovative therapeutic options that ...
WALTHAM, Mass., May 29, 2024 The biopharmaceutical landscape anticipates significant insights as Invivyd, Inc. (Nasdaq: IVVD), a company fervently dedicated to combating serious viral infectious diseases, gears up to present preliminary data from its ongoing CANOPY Phase 3 clinical trial of VYD222 (pemivibart) at two prominent 2024 conferences. The CANOPY trial evaluates the efficacy of VYD222, a monoclonal antibody designed for the pre-exposure prophylaxis of COVID-19. Invivyd’s commitment to addressing global health challenges through innovative therapies takes center stage as the company prepares to share subset analyses at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2...
In a bid to safeguard the vulnerable population from the detrimental impact of viral infectious diseases, pioneering biopharmaceutical company, Invivyd, Inc. (Nasdaq: IVVD), has taken a significant stride forward with the launch of its groundbreaking product, PEMGARDA, now available for purchase in the United States. Alongside this exciting development, the company also unveiled its ambitious net product revenue guidance for 2024, projected to be within the impressive range of $150 million to $200 million.Invivyd has long been at the forefront of cutting-edge medical innovations, driven by a steadfast commitment to protecting the global community against the threat of viral infections. With the introduction ...
PEMGARDA: The Revolutionary Treatment for COVID-19 Pre-Exposure Prophylaxis (PrEP) in Immunocompromised IndividualsIn a groundbreaking announcement, Invivyd, Inc. has unveiled their latest innovation in the fight against COVID-19. The biopharmaceutical company has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for PEMGARDA, formerly known as VYD222. This half-life extended monoclonal antibody (mAb) marks a significant milestone in the prevention of COVID-19 for adults and adolescents (12 years of age and older), who suffer from moderate-to-severe immune compromise due to specific medical conditions or the use of immunosuppressive medications or treatments. This ar...
Invivyd Inc’s Comment on Sales, Marketing and Customers
The company sells its product primarily through third-party specialty distributors and, to a lesser extent, directly to a limited number of infusion centers, healthcare providers, and provider institutions. Shipments are made to sites of care such as provider institutions, infusion centers, and clinics that bill health insurance plans. The company has a third-party logistics agreement with a 3PL Agent responsible for storage, distribution, returns, customer service, logistics, and system support. For the year ended December 31, 2025, net product revenue was derived from sales to third-party specialty distributors and direct sales to select infusion centers, healthcare providers, and provider institutions in the U.S. Three specialty distributors accounted for 46%, 23%, and 17% of total gross sales, respectively. Additionally, the company maintains a relationship with Adimab, which provides antibody discovery, engineering, and optimization services, including agreements for antibody discovery and platform technology use.
Sources:
Invivyd Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Invivyd Inc’s corporate clients.
For your research, we’ve provided 9 tables on Invivyd Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
196.21 %